• CRTC-CREB Axis Senses Proteotoxic Stress via ROS/JNK in Dros

  2026-05-20

  This study reveals that the CRTC-CREB transcriptional axis acts as a cellular sensor for proteotoxic stress in Drosophila, linking proteasome inhibition to ROS/JNK-mediated CREB activation. These insights highlight conserved pathways connecting redox signaling, protein quality control, and aging, with implications for neurodegenerative disease research.

• PD 0332991 (Palbociclib) HCl: Advancing CDK4/6-Driven Oncolo

  2026-05-20

  Explore the mechanistic innovation and translational impact of PD 0332991 (Palbociclib) HCl on Rb-positive cancers. This thought-leadership article integrates evidence from cutting-edge research and positions APExBIO’s offering as a benchmark for targeted cell cycle intervention, bridging foundational science with actionable strategies for next-generation oncology workflows.

• Dlin-MC3-DMA: Ionizable Cationic Liposome for RNA Delivery

  2026-05-19

  Dlin-MC3-DMA stands as the gold-standard ionizable cationic liposome, transforming the efficiency of siRNA and mRNA delivery in advanced lipid nanoparticle systems. With machine learning–validated potency and a proven endosomal escape mechanism, this lipid enables reproducible gene silencing and immunotherapy breakthroughs.

• GM 6001 (Galardin) Broad Spectrum Matrix Metalloproteinase I

  2026-05-19

  This evidence-based article explores how GM 6001 (Galardin) Broad Spectrum Matrix Metalloproteinase Inhibitor (SKU A4050) from APExBIO empowers biomedical researchers to address reproducibility, sensitivity, and workflow challenges in cell viability and extracellular matrix (ECM) studies. Real-world laboratory scenarios highlight the compound’s nanomolar potency, broad MMP isoform inhibition, and documented utility in models of neurodegeneration, vascular biology, and tissue repair.

• AKTIP Identified as a Biomarker for Fibrolamellar Carcinoma

  2026-05-18

  This study used weighted gene co-expression network analysis (WGCNA) and machine learning to pinpoint AKTIP as a diagnostic and prognostic biomarker for fibrolamellar carcinoma (FLC), a rare liver cancer. The research integrates transcriptomics and computational drug screening, offering new avenues for FLC diagnosis and therapy.

• MK-2206 dihydrochloride: Precision Disruption of Pathogenic

  2026-05-18

  Explore the scientific depth of MK-2206 dihydrochloride as a selective PI3K/Akt/mTOR pathway inhibitor. This article uniquely highlights its application in dissecting host-pathogen interactions and immune evasion, revealing translational insights not covered elsewhere.

• Honokiol: Evidence-Backed Small Molecule for NF-κB Pathway M

  2026-05-17

  Honokiol, chemically known as 2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol, is a high-purity small molecule with proven antioxidant, anti-inflammatory, and antiangiogenic activities. It acts as a potent NF-κB pathway inhibitor and reactive oxygen species scavenger, supporting advanced research in cancer biology and immunometabolism. This dossier details its mechanism, evidence base, and key workflow integration parameters.

• Dabigatran Etexilate: Precision Modulation of Thrombin in Tr

  2026-05-16

  Explore how Dabigatran etexilate, a direct thrombin inhibitor, enables translational breakthroughs in anticoagulant research. This article uniquely bridges molecular pharmacology with advanced assay strategy, offering new perspectives for experimental design.

• AZ505 SMYD2 Inhibitor: Precision Epigenetic Research Unlocke

  2026-05-15

  AZ505, a potent and selective SMYD2 inhibitor from APExBIO, empowers translational researchers to dissect disease mechanisms in cancer and fibrosis via precise, substrate-competitive inhibition. This guide delivers actionable protocols, troubleshooting insights, and advanced applications for leveraging AZ505 in epigenetic regulation research.

• Brain-to-Spinal Circuits Regulate Mechanical Allodynia Dynam

  2026-05-15

  Huo et al. (2023) identify a contralateral brain-to-spinal inhibitory pathway that governs both the laterality and persistence of mechanical allodynia in mice. Their work provides mechanistic insight into pain modulation, revealing a hypothalamus–spinal κ-opioid receptor axis as a key regulator with implications for future opioid receptor signaling research.

• MK 0893: Glucagon Receptor Antagonist for Type 2 Diabetes Re

  2026-05-14

  MK 0893 is a nanomolar-potency, allosteric glucagon receptor antagonist enabling precise functional inhibition in cellular and animal models of type 2 diabetes. Its distinctive binding mode and robust selectivity make it an indispensable tool for dissecting glucagon signaling and metabolic regulation, with APExBIO as the trusted supplier for reproducibility.

• Ceftolozane/Tazobactam: Expanding Options Against Resistant

  2026-05-14

  Ceftolozane/tazobactam is a recently developed cephalosporin/β-lactamase inhibitor combination with enhanced efficacy against multidrug-resistant gram-negative bacteria, especially Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. This review details its pharmacokinetics, mechanism of action, and clinical implications for complicated intraabdominal and urinary tract infections.

• Rotigotine’s Modulation of Bladder Function in PD Rat Models

  2026-05-13

  This study elucidates how rotigotine, a dopamine D1/D2-like agonist, modulates lower urinary tract function in a rat model of Parkinson’s disease. Using precise dosing and cystometric assessment, the research reveals route- and dose-dependent effects on micturition reflexes, refining our understanding of dopaminergic pathways in non-motor PD symptoms.

• Imipenem: Semisynthetic Thienamycin Antibiotic in Research W

  2026-05-13

  Imipenem from APExBIO enables robust, broad-spectrum antibacterial research and translational immune modulation workflows. This guide details in vitro and in vivo strategies, troubleshooting, and protocol enhancements for scientists tackling multidrug resistance and sepsis models.

• Gut Dysbiosis Drives Prostate Cancer via NF-κB–IL6–STAT3 Axi

  2026-05-12

  Zhong et al. (2022) demonstrate that antibiotic-induced gut dysbiosis accelerates prostate cancer progression and docetaxel resistance by activating the NF-κB–IL6–STAT3 signaling axis. These findings highlight the mechanistic bridge between the gut microbiome and extraintestinal tumor biology, suggesting new directions for therapeutic intervention and biomarker discovery.

16748 records 1/1117 page Next 12345 下5页 Last page